Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8490
-0.0361 (-4.08%)
At close: Mar 3, 2026, 4:00 PM EST
0.8190
-0.0300 (-3.53%)
Pre-market: Mar 4, 2026, 6:22 AM EST

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
0.491.50.58---
Revenue Growth (YoY)
-62.75%157.63%----
Gross Profit
0.491.50.58---
Selling, General & Admin
5.916.468.4320.9713.5514.93
Research & Development
8.399.367.6392.4223.937.88
Total Operating Expenses
14.3115.8216.06113.3937.4552.81
Operating Income
-13.82-14.32-15.47-113.39-37.45-52.81
Total Non-Operating Income (Expense)
0.781.361.190.730.32-0.67
Pretax Income
-13.04-12.96-14.29-112.66-37.13-53.48
Net Income
-13.04-12.96-14.29-112.66-37.13-53.48
Net Income to Common
-13.04-12.96-14.29-112.66-37.13-53.48
Shares Outstanding (Basic)
664211
Shares Outstanding (Diluted)
664211
Shares Change (YoY)
23.18%52.31%118.31%55.69%0.72%252.08%
EPS (Basic)
-2.15-2.35-3.95-67.99-34.88-50.61
EPS (Diluted)
-2.15-2.35-3.95-67.99-34.88-50.61
Free Cash Flow
-13.44-13.57-12.27-25.01-37.69-41.83
Free Cash Flow Per Share
-2.20-2.46-3.39-15.09-35.41-39.58
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-2829.92%-953.00%-2652.80%---
Profit Margin
-2670.56%-862.43%-2449.59%---
FCF Margin
-2753.58%-903.26%-2103.92%---
EBITDA
-13.8-14.3-15.46-113.21-37.17-52.58
EBITDA Margin
-2825.48%-951.52%-2651.59%---
EBIT
-13.82-14.32-15.47-113.39-37.45-52.81
EBIT Margin
-2829.92%-953.00%-2652.80%---
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q